Analysis of information sources in references of the Wikipedia article "Pramipexole" in English language version.
... features of ICSDs [impulsive-compulsive spectrum disorders] during D2/D3R treatment are consistent with the pharmacological profile of the drugs, the known role of D2/D3R in these behaviors, and the neuroanatomical substrates of D2/D3R-expressing brain systems of ICSDs as shown by modern human imaging studies. While we pose that D2/D3R agonist treatment is sufficient to mediate ICSDs, there likely are many factors that overlay this profile, e.g., genetic vulnerabilities, brain disease state, and maladaptations to the chronic therapy.
… the specific goals of the current review were to … separately identify the RLS-specific side effect, which is augmentation.
… augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy.
Augmentation of symptoms of restless legs syndrome (e.g., earlier onset of symptoms in the evening or afternoon, increase in symptoms, spread of symptoms to involve other extremities) reported; incidence increased with increasing duration of pramipexole treatment.
… the specific goals of the current review were to … separately identify the RLS-specific side effect, which is augmentation.
… augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy.
... features of ICSDs [impulsive-compulsive spectrum disorders] during D2/D3R treatment are consistent with the pharmacological profile of the drugs, the known role of D2/D3R in these behaviors, and the neuroanatomical substrates of D2/D3R-expressing brain systems of ICSDs as shown by modern human imaging studies. While we pose that D2/D3R agonist treatment is sufficient to mediate ICSDs, there likely are many factors that overlay this profile, e.g., genetic vulnerabilities, brain disease state, and maladaptations to the chronic therapy.
… the specific goals of the current review were to … separately identify the RLS-specific side effect, which is augmentation.
… augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy.
... features of ICSDs [impulsive-compulsive spectrum disorders] during D2/D3R treatment are consistent with the pharmacological profile of the drugs, the known role of D2/D3R in these behaviors, and the neuroanatomical substrates of D2/D3R-expressing brain systems of ICSDs as shown by modern human imaging studies. While we pose that D2/D3R agonist treatment is sufficient to mediate ICSDs, there likely are many factors that overlay this profile, e.g., genetic vulnerabilities, brain disease state, and maladaptations to the chronic therapy.
… the specific goals of the current review were to … separately identify the RLS-specific side effect, which is augmentation.
… augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy.
… the specific goals of the current review were to … separately identify the RLS-specific side effect, which is augmentation.
Augmentation of symptoms of restless legs syndrome (e.g., earlier onset of symptoms in the evening or afternoon, increase in symptoms, spread of symptoms to involve other extremities) reported; incidence increased with increasing duration of pramipexole treatment.
… augmentation of the RLS symptoms is a major limitation of oral dopaminergic therapy.
